Mediwound Ltd. · NASDAQ:MDWD
Mediwound — Investor Presentation (August 2026)
31 slides from Mediwound's investor presentation, August 2026
Slide 1: Next-Generation Enzymatic Therapeutics for Non-Surgical Tissue Repair
Next-Generation Enzymatic Therapeutics for Non-Surgical Tissue Repair August 2026 I Nasdaq: MDWD
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our products a
Slide 3: MediWound Company Highlights
MediWound Company Highlights Multibillion-dollar Validated enzymatic Strategic global commercial opportunity technology platform collaborations 14 successful clinical trials Vericel, Mölnlycke, Medline, Solventum, NexoBrid® 150+ peer-reviewed publications Kaken, BARDA, DoW, Essity, B. Braun, Eschar
Slide 4: Core Platform – Enzymatic Biologics for Tissue Repair
Core Platform – Enzymatic Biologics for Tissue Repair High-barrier, proprietary manufacturing process Raw material sourcing Protein (pineapple stem) extraction Purification, enrichment, Complex mixture of stabilization proteolytic enzymes 4
Slide 5: Multi-Billion-Dollar Portfolio: NexoBrid and EscharEx
Multi-Billion-Dollar Portfolio NexoBrid® EscharEx® Disruptive therapy for burn care Investigational next-generation enzymatic therapy for wound care Indication: Eschar removal in deep partial and full-thickness Targeted Indication: Debridement and facilitation of wound closure for thermal burns chro
Slide 6: Product Pipeline
Product Pipeline Indication R&D Phase 1 Phase 2 Phase 3 Registration Marketed Adult burn eschar removal Approved Pediatric burn eschar removal Approved Battlefield burn eschar removal DoW funded Blast injuries and friction burns BARDA funded VLU debridement & facilitation of wound closure Interim as
Slide 7: Multiple Near-Term Value Creating Milestones
Multiple Near-Term Value Creating Milestones 2026 2027 BARDA-VCEL Blast injury Government-related FDA approval agreement program initiation agreements of expanded facility Facility commissioning Manufacturing completed capacity expansion Head-to-head trial PK trial VALUE Phase 3 initiation initiatio
Slide 8: Financial Highlights
Financial Highlights BALANCE SHEET REVENUE EQUITY $36M in cash1 2025 revenue of $17M Outstanding shares: 13.0M NexoBrid® is profitable Fully diluted: 16.8M No debt $120M+ received from BARDA $20M+ funded by DoW • Josh Jennings, MD – TD Cowen • Swayampakula Ramakanth, Ph.D. – H.C. Wainwright MDWD ANA
Slide 9: Projected Revenue Growth Drivers
Projected Revenue Growth Drivers Execution milestones Target revenue ($M) 60.0 50–551,2 2025 2026 2027 2028 50.0 40.0 Commissioning Regulatory 32–351 Expanded facility 30.0 24–261 VALUE Phase 3 FDA/EMA 20.0 17 Commercial readiness / execution 10.0 0.0 2025 2026 (E) 2027 (E) 2028 (E) Government NexoB
Slide 10: Early, effective and selective non-surgical eschar removal for severe burns
Early, effective and selective non-surgical eschar removal for severe burns (8.8% concentration) Validated & commercialized Approved in 40+ countries including U.S., EU, Japan; 18,000+ patients treated to date 10
Slide 11: Eschar Removal - Critical First Step in Burn Care
Eschar Removal - Critical First Step in Burn Care Removal of non-viable tissue is Surgical removal of eschar is critical for wound healing1 traumatic & non-selective2,3 Eschar Prevents infection Stops deterioration Reveals tissue for Loss of healthy tissue Challenging Requires surgical team, and sep
Slide 12: NexoBrid - Non-Surgical, Selective, Effective
NexoBrid® - Non-Surgical, Selective, Effective Indication: Eschar removal of deep partial-thickness and/or full-thickness thermal burns Commercial availability: U.S. (Vericel), Japan (Kaken), EU (direct, and PMI) ▪ Easy-to-use ▪ Enables visual medical assessment ▪ Topical application at patient’s be
Slide 13: Phase 3 Studies Demonstrated Superiority Over SOC
Phase 3 Studies Demonstrated Superiority Over SOC1 Incidence of complete Time to complete Incidence of surgical eschar removal eschar removal Blood loss eschar removal 815 mL 814.51ml 93% 72% 100% p<0.0001 p < 0.0001 p < 0.0001 p < 0.0001 50% 4% 4% 14 mL 0% 10 20 30 40 days NexoBrid N=75 SOC N=75 Ne
Slide 14: NexoBrid – A Strategic Asset for Mass Casualty & Conflict Response
NexoBrid® – A Strategic Asset for Mass Casualty & Conflict Response Real-world combat data Governmental adoption Modern battlefield1 Blast/shrapnel injuries2 BMCI surge capacity3 High incidence of thermal/blast injuries 60% Embedded skin particles impede healing 70% Level of care constrained by surg
Slide 15: Next-Generation Enzymatic Debridement and Facilitation of Wound Healing for Chronic Wounds
Next-Generation Enzymatic Debridement and Facilitation of Wound Healing for Chronic Wounds (5% concentration) Superior to SOC - Clinically de-risked: validated technology $4B TAM opportunity aims to set a new bar for efficacy and successful Phase 2 trials
Slide 16: EscharEx Targets the Three Key Chronic Ulcer Wound Types
EscharEx® Targets the Three Key Chronic Ulcer Wound Types VLU DFU PU Venous leg ulcers Diabetic foot ulcers Pressure ulcers Underlying pathology Chronic venous insufficiency Diabetes (Type I/II) Pressure-induced necrosis Affected area Lower leg or ankle Mostly bottom of the foot Bony prominences (he
Slide 17: EscharEx Achieves Enzymatic Debridement within Days
EscharEx® Achieves Enzymatic Debridement within Days Target Indications: Rapid debridement and facilitation of wound closure via wound bed preparation1 for chronic and hard-to-heal wounds Status: Investigational drug; ongoing Phase 3 in VLU, expansion to DFU & PU in H2 2026 ▪ Debrides chronic ulcers
Slide 18: U.S. KOL Consensus Supports a Non-Invasive First-Line Debridement Approach
U.S. KOL Consensus Supports a Non-Invasive First-Line Debridement Approach Modalities: Efficacy vs. required expertise1,2 Treatment escalation pathway1 Surgical EscharEx® Ultrasonic Surgical / Ultrasonic Biological 3rd line Mechanical Efficacy Sharp / Biological / Sharp 2nd line Mechanical Current E
Slide 19: Three Phase 2 Studies Showed Robust and Consistent Results
Three Phase 2 Studies Showed Robust and Consistent Results WEEKLY FOLLOW- SCREENING DAILY NON-SURGICAL SOC UP 2w 14w EscharEx n=46 RANDOMIZATION ChronEx1 Placebo n=43 ✓ Debridement VLU ✓ Wound bed preparation SOC n=30 ✓ Debridement ✓ Wound bed preparation PharmEx2 EscharEx n=12 ✓ Wound size reductio
Slide 20: Phase 2 MW-EX01 Trial: EscharEx Effective in Both VLU and DFU
Phase 2 MW-EX01 Trial: EscharEx® Effective in Both VLU and DFU Incidence of complete debridement within 2 weeks (VLU, DFU, Traumatic ulcers) 93% of the patients who 55% p = 0.04 completed debridement with EscharEx® achieved full 29% debridement within a week (4–5 daily applications) EscharEx Placebo
Slide 21: Phase 2 ChronEx Trial in VLU: Endpoints Significantly Met
Phase 2 ChronEx Trial in VLU: Endpoints Significantly Met Complete debridement within 2 weeks Time to wound bed prepared (primary endpoint) (complete debridement + healthy granulation tissue) 63% p < 0.001 p = 0.004 30% 13% p = 0.011 p = 0.004 EscharEx® Placebo NSSOC n = 46 n = 43 n = 30 EscharEx 63
Slide 22: Phase 2 PharmEx Trial: EscharEx Surpasses Traditional Debridement
Phase 2 PharmEx Trial: EscharEx® Surpasses Traditional Debridement 70% 64% 35% 100% Complete debridement achieved Bioburden reduced Wound size reduced by end Biofilm substantially reduced within 8 applications by end of treatment of two-week follow-up for all patients positive for (avg. 3.9 applicat
Slide 23: EscharEx Well-Positioned to Become Market Leader
EscharEx® Well-Positioned to Become Market Leader EscharEx® SANTYL Approved in 1965; $400M+ annual revenues (2025) Stage Investigational drug - Phase 3 Existing reimbursement code1 Mechanism of Mixture of enzymes; multiple targets of action Collagenase; single target of action Action Debridement, pr
Slide 24: Head-to-Head Data Shows EscharEx Superiority vs. SANTYL
Head-to-Head Data Shows EscharEx® Superiority vs. SANTYL1 Incidence of complete Time to achieve WBP Time to wound closure Patient-reported pain debridement in 2 weeks p = 0.05 p = 0.014 p = 0.001 1. Dove et al., 2025; WOUNDS 24
Slide 25: VLU VALUE Phase 3 Trial
VLU VALUE Phase 3 Trial1 STUDY DESIGN ENDPOINTS A global (U.S., EU, ROW), randomized, double-blind, adaptive design study in VLU patients Co-Primary: Incidence of complete debridement Two arms: EscharEx vs. placebo, 1:1 ratio Facilitation of wound closure STUDY OBJECTIVES Sample size: 216 VLU patien
Slide 26: DFU Phase 2 Trial
DFU Phase 2 Trial STUDY DESIGN ENDPOINTS A multicenter, prospective, randomized, double-blind, adaptive design study in DFU patients Primary: Time to complete debridement STUDY Two arms: EscharEx vs. placebo, 1:1 ratio Secondary: Incidence of complete debridement OBJECTIVES Sample size: 50 DFU patie
Slide 27: PU Investigator-Initiated Trial
PU Investigator-Initiated Trial STUDY DESIGN ENDPOINTS A prospective, open-label, single-arm, single-dose study in PU patients Descriptive: Incidence of complete debridement Sample size: up to 10 patients with stage II PU with at Incidence of complete healthy granulation tissue STUDY least 50% non-v
Slide 28: Primary Research: EscharEx to Transform the Market
Primary Research: EscharEx® to Transform the Market All care settings report strong drivers for adoption1 EscharEx draws share across all debridement modalities1 1.0% 1.2% 6.4% 5.0% 21% 22% Other 8.5% 10.0% Non-sharp Combo 7.7% 7.7% 4.1% Sharp + Autolytic 3.4% 11.0% SANTYL 9.0% 10.5% 19% 31% Autolyt
Slide 29: $1.05B Projected Peak Sales in $4B TAM in U.S.
$1.05B Projected Peak Sales in $4B TAM in U.S. Etiology prevalence ~ 6.85M Estimated 2028 total patient population 2.42M DFU, 1.68M VLU and 2.75M PU (6.85M total)1 DFU: 2.42M VLU: 1.68M PU: 2.75M Patients who require debridement ~ 4.04M Percent of patients undergoing debridement quantified through s
Slide 30: Experienced Leadership Team
Experienced Leadership Team Nachum (Homi) Shamir Ofer Gonen Dr. Shmulik Hess Dr. Ety Klinger Barry Wolfenson Hani Luxenburg Dr. Robert J. Snyder Chairman CEO COO & CCO Chief Medical Officer EVP Strategy & Corp. Dev. CFO SVP Global Medical Affairs 30
Slide 31: Strategic Timeline
Strategic Timeline NexoBrid revenue: EscharEx program EscharEx Phase 3 EscharEx $17M expansion results FDA approval EscharEx Phase 3 BARDA/DoW collaborations Expanded NexoBrid facility Revenue: $50–55M initiation approval driven by EscharEx Strategic research NexoBrid revenue: Positive operating col